People | February 18, 2022
Lyra Therapeutics appoints Harlan W. Waksal as Executive Chairman
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Go-ahead for pivotal clinical trial which is expected to commence by March
Narayanan to lead SeQuent through next phase of consolidation and growth
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Flattish volume growth and subdued new launches were key factors for last month
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Subscribe To Our Newsletter & Stay Updated
